A 6-week randomized trial found that tirzepatide significantly reduced energy intake, appetite, and cravings in adults with overweight or obesity, outperforming liraglutide and placebo. Brain ...

Ozempic and Mounjaro are both very popular for weight loss at the minute, but there's one big difference between the two ...

Menopause can feel like one big balancing act. Between managing your hormone levels and symptoms like hot flashes, night ...

Researchers found that tirzepatide, a medication primarily used for treating type 2 diabetes and weight loss, reduced body weight, food intake and many measures of appetite more than placebo and ...

“Weight loss quality is a new concept….The discussion no longer revolves around the lack of adequate efficacy but rather ...

Researchers found that tirzepatide, a medication primarily used for treating type 2 diabetes and weight loss, reduced body weight, food intake and many measures of appetite more than placebo and ...

Weight gain, low energy and stalled progress at the gym are issues many men face as they get older. But a new wave of ...

PharmaZee’s weight loss program has gained significant attention for its use of GLP-1 agonists, such as Semaglutide and Tirzepatide, which have been scientifically proven to aid in weight loss ...

We're excited with the results, which demonstrated that low-dose bremelanotide matched tirzepatide in appetite suppression, a compelling outcome," said Carl Spana, Ph.D., President and CEO of Palatin.

New animal research being presented at this year’s European Congress on Obesity (ECO) in Malaga, Spain (11-14 May), reveals distinct metabolic adjustments to tirzepatide and semaglutide ...

Tirzepatide, sold under the name Zepbound, activates two hormone receptors—GLP-1 and GIP—while semaglutide (Wegovy) only targets GLP-1. Both of these hormones help reduce appetite and regulate ...

We're excited with the results, which demonstrated that low-dose bremelanotide matched tirzepatide in appetite suppression, a compelling outcome," said Carl Spana, Ph.D., President and CEO of Palatin.